These findings reinforce the potential involvement of EGFR in pantoprazole-induced osteoporosis and highlight its importance as a therapeutic target for addressing bone metabolism disorders associated with long-term PPIs use. This evidence concerns the gene EGFR and metabolic bone disorder.